Pfizer, OPKO: FDA to Review Somatrogon for Growth-Hormone Deficiency
By Colin Kellaher
Pfizer Inc. and OPKO Health Inc. on Monday said the U.S. Food
and Drug Administration accepted for review their application for
somatrogon, a once-weekly human-growth hormone for pediatric
patients with growth-hormone deficiency.
The companies said the agency set a target action date in
October for somatrogon, which, if approved, would help reduce the
burden of daily growth-hormone injections.
New York drug maker Pfizer and OPKO, a Miami healthcare-services
company, signed a worldwide agreement in 2014 to develop and
commercialize somatrogon for growth-hormone deficiency.
Write to Colin Kellaher at email@example.com
(END) Dow Jones Newswires
January 04, 2021 08:54 ET (13:54 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.